Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

e-cienciaDatos, Repositorio de Datos del Consorcio Madroño
Research data Set de datos (Dataset)

Pharmacological inhibition of mTORC1 reduces neural death and damage volumen after MCAO by modulating microglial reactivity

  • Villa González, Mario
  • Rubio, Marina
  • Martín López, Gerardo
  • R. Mallavibarrena, Paula
  • Vallés Saiz, Laura
  • VIVIEN, DENIS
  • Wandosell, Francisco
  • Perez Alvarez, Maria Jose
<p>Ischemic stroke is a sudden and acute disease characterized by neuronal death, increment of reactive gliosis (reactive microglia and astrocytes), and a severe inflammatory process. Neuroinflammation is an early event after cerebral ischemia, with microglia playing a leading role. Reactive microglia involve functional and morphological changes that drive a wide variety of phenotypes. In this context, deciphering the molecular mechanisms underlying such reactive microglial is essential to devise strategies to protect neurons and maintain certain brain functions affected by early neuroinflammation after ischemia. Here, we studied the role of mammalian target of rapamycin (mTOR) activity in the microglial response using a murine model of cerebral ischemia in the acute phase. We also determined the therapeutic relevance of the pharmacological administration of rapamycin, a mTOR inhibitor, before and after ischemic injury. Our data show that rapamycin, administered before or after brain ischemia induction, reduced the volume of brain damage and neuronal loss by attenuating the microglial response. Therefore, our findings indicate that the pharmacological inhibition of mTORC1 in the acute phase of ischemia may provide an alternative estrategia to reduce neuronal damage through attenuation of the associated neuroinflammation.</p> <p>This dataset contains the raw data of cuantificación used in this study. It includes all the observations and measurements that were collected, which are essential for analysis and interpretation. The data is organized in a way that facilitates further exploration and analysis, ensuring that researchers can effectively utilize it for their own studies.</p>
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Experimental Models for Aging and their Potential for Novel Drug Discovery

  • Folch, Jaume
  • Busquets, Oriol|||0000-0002-1372-9699
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Sánchez-López, Elena|||0000-0003-2571-108X
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Beas-Zarate, Carlos
  • Marin, Miguel
  • Casadesus, Gemma|||0000-0002-5206-5637
  • Olloquequi, Jordi|||0000-0002-6492-2739
  • Auladell, Carme|||0000-0001-8345-1859
  • Camins, Antoni|||0000-0002-1229-5956
An interesting area of scientific research is the development of potential antiaging drugs. In order to pursue this goal, it is necessary to gather the specific knowledge about the adequate preclinical models that are available to evaluate the beneficial effects of new potential drugs. This review is focused on invertebrate and vertebrate preclinical models used to evaluate the efficacy of antiaging compounds, with the objective to extend life span and health span. Research and online content related to aging, antiaging drugs, experimental aging models is reviewed. Moreover, in this review, the main experimental preclinical models of organisms that have contributed to the research in the pharmacol-ogy of lifespan extension and the understanding of the aging process are discussed. Dietary restriction (DR) constitutes a common experimental process to extend life span in all organisms. Besides, classical antiaging drugs such as resveratrol, rapamycin and metformin denominated as DR mimetics are also discussed. Likewise, the main therapeutic targets of these drugs include sirtuins, IGF-1, and mTOR, all of them being modulated by DR. Advances in molecular biology have uncovered the potential molecular pathways involved in the aging process. Due to their characteristics, invertebrate models are mainly used for drug screening. The National Institute on Aging (NIA) developed the Interventions Testing Program (ITP). At the pre-clinical level, the ITP uses Heterogeneous mouse model (HET) which is probably the most suitable rodent model to study potential drugs against aging prevention. The accelerated-senescence mouse P8 is also a mammalian rodent model for aging research. However, when evaluating the effect of drugs on a preclinical level, the evaluation must be done in non-human primates since it is the mammalian specie closest to humans. Research is needed to investigate the impact of new potential drugs for the increase of human quality of.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Annexin A5 prevents amyloid-β-induced toxicity in choroid plexus, implication for Alzheimer's disease

  • Bartolome, Fernando|||0000-0001-9322-8933
  • Krzyzanowska, Agnieszka
  • de la Cueva, Macarena
  • Pascual, Consuelo
  • Antequera, Desiree
  • Spuch, Carlos
  • Villarejo-Galende, Alberto|||0000-0002-6834-7620
  • Rábano, Alberto|||0000-0001-9320-6566
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Ferrer, Isidro|||0000-0001-9888-8754
  • Hardy, John|||0000-0002-3122-0423
  • Abramov, Andrey Y.
  • Carro, Eva|||0000-0002-6504-4579
In Alzheimer's disease (AD) amyloid-β (Aβ) deposits may cause impairments in choroid plexus, a specialised brain structure which forms the blood-cerebrospinal fluid (CSF) barrier. We previously carried out a mass proteomic-based study in choroid plexus from AD patients and we found several differentially regulated proteins compared with healthy subjects. One of these proteins, annexin A5, was previously demonstrated implicated in blocking Aβ-induced cytotoxicity in neuronal cell cultures. Here, we investigated the effects of annexin A5 on Aβ toxicity in choroid plexus. We used choroid plexus tissue samples and CSF from mild cognitive impairment (MCI) and AD patients to analyse Aβ accumulation, cell death and annexin A5 levels compared with control subjects. Choroid plexus cell cultures from rats were used to analyse annexin A5 effects on Aβ-induced cytotoxicity. AD choroid plexus exhibited progressive reduction of annexin A5 levels along with progressive increased Aβ accumulation and cell death as disease stage was higher. On the other hand, annexin A5 levels in CSF from patients were found progressively increased as the disease stage increased in severity. In choroid plexus primary cultures, Aβ administration reduced endogenous annexin A5 levels in a time-course dependent manner and simultaneously increased annexin A5 levels in extracellular medium. Annexin A5 addition to choroid plexus cell cultures restored the Aβ-induced impairments on autophagy flux and apoptosis in a calcium-dependent manner. We propose that annexin A5 would exert a protective role in choroid plexus and this protection is lost as Aβ accumulates with the disease progression. Then, brain protection against further toxic insults would be jeopardised.